Compare ARI & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARI | TRVI |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2009 | 2019 |
| Metric | ARI | TRVI |
|---|---|---|
| Price | $11.16 | $15.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $11.00 | ★ $21.55 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.03% | N/A |
| EPS Growth | ★ 183.51 | 31.91 |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $271,589,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.09 | $5.38 |
| 52 Week High | $11.24 | $14.75 |
| Indicator | ARI | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 64.90 | 77.85 |
| Support Level | $9.59 | $10.07 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.18 | 0.92 |
| MACD | 0.06 | 0.30 |
| Stochastic Oscillator | 89.35 | 91.68 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.